Atlas FDA

SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-the-Wire), SYNERGY XD Everolimus-E

FDA premarket approval P150003/S077 · decided 2021-07-02

Approval details

PMA number
P150003
Supplement
S077
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-the-Wire), SYNERGY XD Everolimus-E
Generic name
Coronary drug-eluting stent
Applicant
Boston Scientific Corporation
Date received
2021-06-22
Decision date
2021-07-02
Days to decision
10 days
Decision code
OK30
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Maple Grove, MN
Statement
Introduction of an automated loading process of corewire and hypotube components and an automated vision system.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
TheraSphere 360™ Y-90 Management Platform (K262462)Boston Scientific Corporation2026-07-24
FARADRIVE™ Steerable Sheath (M004PF21M402) (K262165)Boston Scientific Corporation2026-07-24
OBSIDIO Conformable Embolic (K261488)Boston Scientific Corporation2026-07-24
WallFlex Esophageal Stent System;Agile Esophageal Over-the-Wire (OTW) Stent System (K261978)Boston Scientific Corporation2026-07-10
RIVOS™ EUS Access Device (M00553900) (K260428)Boston Scientific Corporation2026-06-17
MOSES Raydar™ (K260100)Boston Scientific Corporation2026-05-18
TruSelect™ 2.6 Microcatheter (K260771)Boston Scientific Corporation2026-05-15
Asurys Fluid Management System (K251273)Boston Scientific Corporation2026-03-27